Effects of repeated administration of methylphenidate on reproductive parameters in male rats  by Montagnini, Bruno Garcia et al.
Physiology & Behavior 133 (2014) 122–129
Contents lists available at ScienceDirect
Physiology & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /phbEffects of repeated administration of methylphenidate on reproductive
parameters in male ratsBruno Garcia Montagnini a, Luiza Sienna Silva a, Alice Hartmann dos Santos a,
Janete Aparecida Anselmo-Franci c, Glaura Scantamburlo Alves Fernandes b,
Suzana de Fátima Paccola Mesquita b, Daniela Cristina Ceccatto Gerardin a,⁎
a Department of Physiological Sciences, State University of Londrina, 86051-980 Londrina, Paraná, Brazil
b Department of Biology, State University of Londrina, 86051-980 Londrina, Paraná, Brazil
c Department of Morphology, Estomatology and Physiology, University of São Paulo, 14040-900 Ribeirão Preto, São Paulo, Brazil
H I G H L I G H T S
• Early MPH treatment induces persistent alterations in reproductive parameters.
• MPH treatment affects sperm morphology and germ cell population.
• MPH treatment does not affect the sexual behavior in male rats.Abbreviations:ADHD, attention deﬁcit hyperactivity di
DA, dopamine; PND, post-natal day; AGD, anogenital dist
⁎ Corresponding author at: Department of Physiologic
Londrina-UEL, 86051-980 Londrina, Paraná, Brazil. Tel.: +
3371 4467.
E-mail address: dcgerardin@uel.br (D.C.C. Gerardin).
http://dx.doi.org/10.1016/j.physbeh.2014.05.016
0031-9384/© 2014 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 April 2014
Received in revised form 5 May 2014
Accepted 16 May 2014
Available online 24 May 2014
Keywords:
Attention-deﬁcit/hyperactivity disorder
Methylphenidate
Development
Spermatogenesis
Testicle
Sperm morphologyMethylphenidate (MPH) is a psychostimulant drug which acts by blocking the dopamine and norepinephrine
transporters and is the main drug used to treat attention deﬁcit hyperactivity disorder in children and adoles-
cents. During puberty, changes in neurotransmitter systems (including dopaminergic system) are engaged on
the release of gonadal hormones and the development of cephalic structures responsible for reproductive func-
tion. This study investigated the effects of repeated treatment with methylphenidate during development on
reproductive parameters of adult male rats. Wistar rats received MPH 2.5 mg/kg, MPH 5.0 mg/kg, or distilled
water (gavage) from postnatal day (PND) 21 to PND 60. At PND 100, an increase in percentage of abnormal
tail morphology sperm in MPH 2.5 and increase in testicular interstitial tissue volume in MPH groups as well
as in the number of type A spermatogonia inMPH5.0 groupwere observed. This studydemonstrated that repeat-
ed administration of methylphenidate during periods corresponding childhood to early adulthood interfered on
testicular function in rats at adult life.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
The attention deﬁcit hyperactivity disorder (ADHD) is one of the
most frequent neuropsychiatric disorders commonly diagnosed in
children and adolescents. Its worldwide prevalence is of 5.29% [1] and
is deﬁned by persistent symptoms of inattention, hyperactivity and
impulsivity [2].
Although ADHD has been established as a disorder acquired during
childhood [3], longitudinal follow-up studies reported that ADHDsorder;MPH,methylphenidate;
ance; HTF, human tubular ﬂuid.
al Sciences, State University of
55 43 3371 4307; fax: +55 43symptoms diagnosed during infancy could persist into adulthood with
a margin that exceeds 60% [4–6].
For this psychiatric disease, methylphenidate (MPH) is the main
psychostimulant drug prescribed to children and adolescents to treat
ADHD [7–9]. It acts by blocking the dopamine (DA) and noradrenaline
(NA) transporters [10,11], although it is suggested that the therapeutic
effect of MPH is mainly due to the DA transporter blockade [12].
Some studies have evidenced the DA role on the pre-pubertal matu-
ration stages in different vertebrate species [13–15]. It is known that
early exposure to MPH could lead to long-lasting alterations in brain
DA pathways and natural reward systems [16,17], which are related to
sexual behavior performance [18]. In this sense, impairment of sexual
behavior performance was demonstrated in adult rats treated with
MPH during adolescence [17], and alterations on hormonal proﬁle
[19] and spermatogenesis [20,21] were observed shortly after drug
discontinuation.
Fig. 1. Diagram of the experimental design. PND: postnatal day.
Fig. 2. Body weight of male rats during treatment period. Data are means ± S.E.M.
RMANOVA (p N 0.05). CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg; MPH
5.0: methylphenidate 5.0 mg/kg.
123B.G. Montagnini et al. / Physiology & Behavior 133 (2014) 122–129Based on these considerations, this study was conducted in order to
evaluate the enduring effects on reproductive function in adult male
rats submitted to similar MPH treatment established for ADHD, from
late infancy to early adulthood periods [22].
2. Materials and methods
2.1. Animals and treatment
A total of 10 male and 20 female Wistar rats (85–90 days) from the
colony of the State University of Londrina (UEL) were used as parental
generation. They were kept in a controlled environment with tempera-
ture at 21 ± 2 °C; 12 h light/dark cycle (lights on at 6:00 a.m.) and had
free access to regular lab chow (Nuvital™, Paraná, Brazil) and tapwater.
Rats were mated (2 females and 1 male per cage) and gestational day 0
was determined if there were sperm and estrus phase cells in vaginal
smears. On post-natal day (PND) 4, litters were culled to 8 pups keeping
4 males and 4 females wherever possible. Male pups were weaned on
PND 21 and divided into three groups (26 males/group).
– Control group (CTR): received distilled water daily, by gavage, from
PND 21 to PND 60;
– MPH2.5mggroup (MPH2.5): received 2.5 mg/kg ofMPH (Ritalin™,
Novartis) daily, by gavage, from PND 21 to PND 60;
– MPH5.0mggroup (MPH5.0): received 5.0 mg/kg ofMPH (Ritalin™,
Novartis) daily, by gavage, from PND 21 to PND 60.
To avoid the sibling effects, no littermates were used for the same
group. Rats were daily treated at 4–6 p.m. The drug was dissolved in
distilled water immediately prior to the treatment.
In children, the effective dose range is 0.3–1.0 mg/kg MPH [23].
Applying the BW3/4 scaling [24], the equivalent dose in rats would be
1.7–5.5 mg/kg. The highest dose used in this study (5.0 mg/kg) would
be equivalent to a clinically relevant dose in humans and higher doses
were not tested since it is already described in the literature that oral
administration of 5.0 mg/kg does not compromise weight gain [7].
The oral gavage method was chosen in order to provide the same
administration route used in humans.
All animal procedures were approved by the UEL Ethics Committee
for Animal Research (CEUA 16381.2012.45). The experimental protocol
is diagramed in Fig. 1.
2.2. Parameters analyzed during development (PND 21–60)
2.2.1. Body weight
The bodyweightwasmeasured daily during the treatment period as
well as toxicity signs (e.g. lacrimation, piloerection, unusual respiratory
pattern and tremors) were observed.
2.2.2. Physical sexual development
The anogenital distance (AGD, distance from the anus to the genital
tubercle) was obtained weekly (PND 21, 28, 35, 42) through a vernier
caliper until occurrence of preputial separation. AGD was normalized
through its division by the cube root of body weight. From PND 45[25], preputial separation was veriﬁed daily and considered as an
indicator of the sexual maturity onset.
2.3. Parameters analyzed in adulthood (PND 100)
For the evaluation of male reproductive development, each
group (CTR, MPH 2.5 and MPH 5.0) was divided into 2 subgroups
(n = 11–15/subgroup): one group for testosterone level, sexual
organ weight, sperm parameters and testis histomorphometric
analysis and the other one for the sexual behavior evaluation.
2.3.1. Plasmatic testosterone quantiﬁcation
Male rats were euthanized with diethyl ether and blood samples
were collected from the abdominal aorta into syringes containing
heparin, always at the same time. Immediately after collection, blood
sampleswere centrifuged (2500 rpm for 20min at 2 °C) and the plasma
was frozen until assayed. Blood plasma testosterone was measured by
radioimmunoassay using ImmuChem™ Double Antibody 125I RIA Kit
(MP Biomedicals, Orangeburg, NY) according to the manufacturer's
instructions. Samples were analyzed in a double assay format, the
intra-assay coefﬁcient of variation and the minimum sensitivity of the
assay were 10.1% and 0.035 ng/ml respectively.
2.3.2. Collection of tissue and organs
The right testis and epididymis, vas deferens, ventral prostate and
seminal vesicle (without the coagulating gland and full of secretion)
were removed and their weights (absolute and relative to body
weight) were determined. The right testis and epididymis were
frozen at −20 °C for sperm counting. The left testis was collected
for histomorphometric analysis.
2.3.3. Daily sperm production per testis, sperm number and transit time in
the epididymis
Right testis was decapsulated and the caput/corpus and cauda
segments from epididymis were separated. Homogenization-resistant
testicular spermatids (stage 19 of spermiogenesis) and sperm in the
caput/corpus epididymis and cauda epididymis were assessed as
Table 1
Body weight and wet weight of organs from male rats at PND 100.
CTR [15] MPH 2.5 [15] MPH 5.0 [14]
Final body weight (g) 369.710 ± 6.673 358.910 ± 9.626 374.341 ± 12.070
Absolute weights (g)
Testicle (right) 1.492 ± 0.041 1.472 ± 0.069 1.520 ± 0.027
Vas deferens 0.086 ± 0.003 0.081 ± 0.002 0.088 ± 0.003
Epididymis 0.501 ± 0.012 0.488 ± 0.011 0.509 ± 0.012
Prostate 0.377 ± 0.019 0.370 ± 0.018 0.372 ± 0.028
Full seminal vesicle 0.603 ± 0.031 0.550 ± 0.033 0.598 ± 0.031
Empty seminal vesicle 0.172 ± 0.013 0.177 ± 0.010 0.183 ± 0.009
Relative weights
(g/100 g)
Testis (right) 0.404 ± 0.011 0.423 ± 0.018 0.410 ± 0.013
Vas deferens 0.023 ± 0.001 0.023 ± 0.001 0.024 ± 0.001
Epididymis 0.136 ± 0.004 0.137 ± 0.005 0.137 ± 0.004
Prostate 0.102 ± 0.005 0.104 ± 0.005 0.100 ± 0.007
Full seminal vesicle 0.166 ± 0.008 0.154 ± 0.010 0.161 ± 0.008
Empty seminal vesicle 0.047 ± 0.003 0.050 ± 0.003 0.049 ± 0.003
Data are means ± SEM. Numbers in brackets represent the number of animal/group.
ANOVA, p N 0.05. CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg; MPH 5.0:
methylphenidate 5.0 mg/kg.
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et al. [27]. Mature spermatids were counted in a Neubauer chamber. To
calculate daily sperm production (DSP), the number of spermatids at
stage 19was divided by 6.1,which is the number of days in one seminif-
erous cycle when these spermatids are present in the seminiferous
epithelium. Sperm transit time through the epididymiswas determined
by dividing the number of sperm in each segment by the DSP.
2.3.4. Sperm motility, viability and morphology
Sperm motility analysis was performed according to Perobelli et al.
[28] and Favareto et al. [29]. Sperm were obtained from the right vas
deferens and diluted in 1 ml of modiﬁed HTF (Human Tubular Fluid,
Irvine Scientiﬁc™) pre-warmed at 34 °C. A 10 μl aliquot was placed in
a Makler chamber (Irvine) and analyzed under a phase-contrast micro-
scope (OSM-223287, Olympus) at 100× magniﬁcation. One hundred
sperms were evaluated per animal and were classiﬁed as motile or
immotile [28].
For sperm viability, the one step eosin–nigrosin staining technique
was used [30]. 50 μl of spermatozoa in HTF was mixed with eosin–
nigrosin and directly examined, and 100 sperms per animal were
evaluated and classiﬁed as viable or non-viable.
The evaluation of sperm morphology was performed according to
Fernandes et al. [27]. Sperm were recovered from the left vas deferens
by ﬂushingwith 1ml of formol-saline (10%) and smears were prepared
on histological slides that were left to dry for 90 min. It was analyzed
200 spermatozoa per animal in a phase-contrast microscope (400×Table 2
Sperm parameters of adult male rats at PND 100.
Parameters CTR [15]
No. of spermatids (106/testis) 136.258 ±
No. of spermatids (106/g/testis) 98.854 ± 4
DSP 21.457 ± 1
No. of spermatozoa × 106/caput + corpus of epididymis 71.872 ± 4
No. of spermatozoa × 106/g/caput + corpus of epididymis 272.204 ±
No. of spermatozoa × 106/cauda of epididymis 109.486 ±
No. of spermatozoa × 106/g/cauda of epididymis 542.817 ±
Sperm transit time (days) through caput/corpus of epididymis 3.481 ± 0.2
Sperm transit time through cauda of epididymis (days) 5.257 ± 0.4
Abnormal head morphology sperm (%) 15.067 ± 1
Abnormal tail morphology sperm (%) 1.167 ± 0.1
Viable sperm (%) 84.550 ± 2
Mobile sperm (%) 78.500 ± 2
Data are means ± SEM. Numbers in brackets represent the number of animal/group. DSP: dail
methylphenidate 5.0 mg/kg.
⁎ p b 0.05 compared to CTR (ANOVA complemented with Bonferroni).magniﬁcation) [31]. Morphological abnormalities were classiﬁed
into two general categories: head morphology (without characteristic
curvature or isolated form, i.e., no tail attached) and tail morphology
(broken or isolated i.e., no head attached) [32].
2.3.5. Morphometric analysis
The left testis was preserved in 4% glutaraldehyde 0.01 M pH 7.2
sodium phosphate buffer. The fragments were routinely processed for
embedding in plastic resin glycolmethacrylate (Historesin Embedding
kit, Leica™). Histological sections of 5 μm were stained in sodium
borate/toluidine blue at 0.1% [33] and analyzed under a phase-
contrast microscope (OSM-223287, Olympus).
2.3.5.1. Testis stereology. The diameter of the seminiferous tubules was
measured at 100× magniﬁcation using an ocular micrometer. Fifteen
cross sections of tubule proﬁles that were either round or nearly
round were chosen randomly and measured for each animal. The
volume densities of testicular tissue components were determined by
light microscopy using a 100-intersection grid placed in the ocular of
the lightmicroscope. A total of 10 (1000 points) randomly chosen ﬁelds
were scored for each animal at 400×magniﬁcation. The volume of each
component of the testis was determined as the product of the volume
density and testis volume. For subsequent stereological calculations,
the speciﬁc gravity of testis tissue was considered to be 1.0 [34]. To
obtain a more precise measure of testis volume, the testis capsule was
excluded from the testis weight. The total length (inmeters) of seminif-
erous tubules (LST) was estimated by the tubule seminiferous volume
(TSV) in the testis and the average area of tubules obtained from
each animal (πR2; R = tubular diameter / 2, according to the formula:
LST= TSV / πR2) [35,36].
2.3.5.2. Cell numbers. To estimate the number of the different types of
cells that compose the seminiferous epithelium in stage VII, the germ
cell nuclei (spermatogonia A; spermatocyte I in preleptotene/leptotene;
spermatocyte in pachytene; round spermatids) and Sertoli cell nucleo-
lus were counted in 5 round seminiferous tubule cross-sections, chosen
at random for each animal. For this purpose, the diameters of 10 nuclei
(from germinative cells) or nucleoli (from Sertoli cells) were measured
per animal. These counts were corrected for section thickness and
for nucleus or nucleolus diameter, based on the procedure described
by Abercrombie [37] and modiﬁed by Amann & Almquist [38].
Estimates on Sertoli cell number per testicle were performed based
on the Sertoli cell nucleolus corrected number per seminiferous tubule
transversal section in stage VII and the total length of seminiferous
tubule per testicle, following the formula by Hochereau-de Reviers
and Lincoln [39]. The Sertoli cell index (SCI) was obtained from the
ratio between the number of round spermatids per cross section andMPH 2.5 [15] MPH 5.0 [14]
8.072 123.232 ± 10.621 130.451 ± 8.089
.370 93.893 ± 6.946 98.080 ± 6.586
.102 19.784 ± 1.702 21.394 ± 1.323
.995 65.180 ± 6.449 73.660 ± 4.566
17.986 265.957 ± 27.203 284.510 ± 17.353
8.743 94.661 ± 10.365 106.029 ± 7.341
42.675 449.199 ± 44.807 512.051 ± 29.515
77 3.437 ± 0.290 3.546 ± 0.274
57 4.798 ± 0.483 5.137 ± 0.470
.091 18.600 ± 1.288 15.964 ± 1.358
52 2.267 ± 0.271⁎ 1.786 ± 0.313
.091 [12] 78.550 ± 1.397 [11] 78.700 ± 3.037 [10]
.278 [12] 75.000 ± 2.153 [11] 72.600 ± 4.455 [10]
y sperm production. CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg; MPH 5.0:
Table 3
Volumetric composition of testicular parenchyma (μl) of male rats at PND 100.
CTR [14] MPH 2.5 [14] MPH 5.0 [11]
Parenchyma 1390.930 ± 40.864 1428.070 ± 40.434 1415.360 ± 31.015
Seminiferous tubules 1124.140 ± 39.731 1088.000 ± 37.880 1068.270 ± 27.097
Interstitial tissue 266.790 ± 12.562 337.930 ± 15.198⁎ 347.090 ± 17.855⁎
Leydig cells 35.771 ± 2.134 34.663 ± 1.987 35.612 ± 2.233
Data are means ± SEM. Numbers in brackets represent the number of animal/group. CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg; MPH 5.0: methylphenidate 5.0 mg/kg.
⁎ p b 0.05 compared to CTR (ANOVA complemented with Bonferroni).
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tubules.
The individual volume of the Leydig cells was obtained from nucleus
volume and the proportion between nucleus and cytoplasm. The Leydig
cell nucleus volumewas obtained from the knowledge of the mean nu-
clear diameter. For this purpose, ﬁfteen nuclei weremeasured at 1000×
for each animal. Leydig cell nuclear volume (μm3) was obtained by the
formula 4/3πR3, were R = nuclear diameter / 2. To calculate the
proportion between nucleus and cytoplasm a 100-point square lattice
was placed over the sectioned material at 400× magniﬁcation. One
thousand points over Leydig cells were counted for each animal. The
number of Leydig cell per testis was estimated from the Leydig cell
individual volume and the volume occupied by Leydig cell in the testis
parenchyma [40].
2.3.6. Sexual behavior evaluation
All behavioral assessments were performed in adult rats (beginning
on PND 100) during the dark phase of a reversed light/dark cycle, under
dim red light. The animals were allowed a 15-day period of adaptation
to the reversed light/dark cycle before the beginning of the evaluations.
The observations always started 4 h after the onset of darkness and
were recorded by a video camera, linked to a monitor in an adjacent
room.
2.3.6.1. Copulatory behavior. For the copulatory behavior evaluation,
each male was placed into a Plexiglass cage with 20 × 40 × 50 cm
(height × width × length) and, after 5 min, a female in natural
estrous was introduced into the cage. As described previously [41],
during 30 min, the following parameters were recorded: intromission
(vaginal penetration, this behavior starts with a mount, but suddenly
the male makes a deep thrust forward and stops pelvic thrusting, then
vigorously withdraws and always licks his genitals), and ejaculation
(starts with an intromission, but after vaginal penetration the male
remains on the female for 1–3 s) latencies; and the total number of
intromissions and ejaculations. If a male did not mount within 10 min,
the evaluation was interrupted and repeated another day with another
female. If the male failed again in the second evaluation, it was
considered sexually inactive [42].Fig. 3. Photomicrographs of seminiferous tubule sections of rats fromCTR group (A),MPH2.5 gr
seminiferous tubules (ST) in theMPH groups and comparison with the CTR group. Scale= 50 μ
5.0 mg/kg.2.3.6.2. Sexual incentive motivation. The same animals evaluated for
copulatory behavior were submitted to the sexual incentive motivation
(SIM) test. In this test, a rectangular arena with 50 × 50 × 100 cm
(height × width × length) that presents two openings that communi-
cate with two small arenas with 25 cm2 was used . The small arenas
were diagonally opposed to each other and the communication with
themain arena is closed with wire mesh. For the test, an estrous female
(sexual incentive) was placed in one of the small arenas and a sexually
active male (social incentive) was placed in the other one. The ﬂoor of
the main arena had two 25 cm2 divisions (zones) in front of each
small arena opening, named sexual incentive and social incentive
zones, respectively. The experimental male was placed in the center of
the main arena and observed for 20 min. The number of visits and the
total time spent visiting each zone were quantiﬁed, and a preference
score was calculated as (time spent in female zone / total time spent
in both incentive zones) × 100 [43].
2.4. Statistical analysis
Initially, an exploratory analysis was conducted to evaluate normal
distribution (Shapiro–Wilk test) and homogeneity of variance (Levene's
test) of each variable. Variables that presented normal distribution and
homogeneity of variancewere analyzed byANOVA complementedwith
Bonferroni post-hoc test. Conversely, for other variables Kruskal–Wallis
complemented with Dunn's test was performed. For body weight and
AGD (PND 21, 28, 35 and 42), repeated measures ANOVA (RMANOVA)
was applied with day as the within-subject factor and treatment as
the between-subject factors. Differences were considered signiﬁcant if
p b 0.05.
3. Results
3.1. Development (PND 21–60)
3.1.1. Body weight and physical development
Body weight is given in Fig. 2. The repeated administration of MPH
did not affect body weight [F(2,75) = 2.63, p = 0.08], relative AGD
(mm/g1/3) (data not shown), as well the day of preputial separationoup (B) and theMPH5.0 group (C) stainedby toluidine blue. Increase in the space between
m. CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg;MPH 5.0:methylphenidate
Table 4
Biometric parameters of testicular parenchyma of male rats at PND 100.
CTR [14] MPH 2.5 [14] MPH 5.0 [11]
Diameter of seminiferous tubules (μm) 427.563 ± 7.988 413.606 ± 8.365 407.039 ± 4.490
Total length of seminiferous tubules (m) 7.877 ± 0.297 8.194 ± 0.376 8.218 ± 0.200
Leydig cell per testis (106) 29.464 ± 2.022 32.121 ± 2.472 36.435 ± 2.609
Sertoli cell per testis (107) 2.263 ± 0.099 2.125 ± 0.141 2.273 ± 0.098
Sertoli cell index (SCI) 6.210 ± 0.330 7.249 ± 0.474 6.519 ± 0.308
Data aremeans ± SEM. Numbers in brackets represent the number of animal/group. ANOVA, p N 0.05. CTR: distilled water;MPH 2.5:methylphenidate 2.5 mg/kg;MPH 5.0: methylphe-
nidate 5.0 mg/kg.
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49.31 ± 0.62; MPH 5.0 group = 49.12 ± 0.61.
3.2. Adulthood (PND 100)
3.2.1. Body weight and reproductive organ weight
The body weight and reproductive organ weight of adult male
are given in Table 1. No signiﬁcant differences as a result of the MPH
treatment were found in body weight [F(2,43) = 0.68, p = 0.51]. Mean
weights (absolute and relative to body weight) of testes, epididymis,
vas deferens, seminal vesicle and prostate were similar among
experimental groups.
3.2.2. Plasma testosterone quantiﬁcation
The repeated administration of MPH did not cause signiﬁcant
alteration in the plasma testosterone level in adulthood (CTR group:
2.78 ± 0.86, n = 10; MPH 2.5 group: 2.57 ± 0.57, n = 11; and MPH
5.0 group: 2.31 ± 0.43, n = 12, ng/ml) [F(2,32) = 0.15, p = 0.86].
3.2.3. Sperm analysis
Data from sperm parameters are shown in Table 2. There was no
effect of MPH treatment on sperm count, motility and viability in either
dose. However, the results given by sperm morphology revealed a
signiﬁcant increase in abnormal tail morphology in MPH 2.5 group
[F(2,43) = 4.90, p = 0.01] when compared to CTR group.
3.2.4. Histomorphometric evaluation
As seen in Table 3, both MPH doses promoted a signiﬁcant [F(2,38) =
8.71, p = 0.001] increase in the interstitial tissue volume compared to
CTR group (ANOVA complemented with Bonferroni). Fig. 3 demon-
strates the seminiferous tubules and the interstitial tissue differences
among groups.
In Table 4, the morphometric values of testicular parenchyma are
presented. No change in diameter [F(2,38) = 1.90, p = 0.16] and total
length of seminiferous tubules [F(2,38) = 0.38, p = 0.69], number of
Leydig [F(2,38) = 2.08, p = 0.14] and Sertoli cells [F(2,38) = 0.51, p =
0.61], as well as Sertoli cell index [F(2,38) = 2.00, p = 0.15] was found.
Values for the germ cell population are shown in Table 5. Bonferroni
post hoc analyses revealed a signiﬁcant increase of type A spermatogo-
nia in MPH 5.0 group [F(2,38) = 3.58, p = 0.04] and decrease of
spermatocyte I in the preleptotene/leptotene phase in MPH 2.5 group
[F(2,38) = 4.73, p = 0.02] compared to CTR group.Table 5
Corrected cell population by tubule cross section at stage VII of the cycle of the seminiferous e
CTR [14]
Type A spermatogonia 0.466 ± 0.025
Spermatocyte I in the preleptotene phase 27.877 ± 0.943
Spermatocyte I in the pachytene phase 29.135 ± 1.503
Round spermatids 87.566 ± 2.851
Sertoli cell nucleolus 14.548 ± 0.713
Data are means ± SEM. Numbers in brackets represent the number of animal/group. CTR: dist
⁎ p b 0.05 compared to CTR (ANOVA complemented with Bonferroni).3.2.5. Sexual behavior evaluation
The sexual behavior evaluation results are shown in Table 6. The
repeated MPH treatment did not inﬂuence either copulatory behavior
or sexual motivation parameters (CTR group: n = 11; MPH 2.5 group:
n = 11; MPH 5.0 group: n = 12, p N 0.05) in adult rats.4. Discussion
The growth pattern of an animal during treatment is a reliable
indicator in the investigation of toxic effects [44]. In humans, the loss
of weight is the most common adverse effect associated with MPH
treatment and usually disappears with time [45,46]. In rats, studies
have shown that oral MPH treatment decreases body weight in a
dose-dependent manner, as observed in neonatal rats at doses
above 50 mg/kg/day [7], as well as in adult rats in daily doses above
20 mg/kg [47]. In the present study, the MPH administrations did not
induce body weight reduction during the treatment period. It is already
described in the literature that daily doses of 5 mg/kg (via gavage) do
not induce body weight loss during development [7]. In that way, in
order to rule out the possibility of reproductive disturbances incurred
byweight loss, since the decrease in this parameter is related to changes
in sexual maturation [48,49], MPH doses that have no inﬂuence in body
weight were selected.
In the current study, male rats were treated with MPH during the
puberty period, period in which major rearrangement in architecture
and brain plasticity occurs, deﬁning neuroendocrine and behavioral
changes that can persist throughout life [50]. Puberty initiates by the re-
surgence of a pulsatile proﬁle of hypothalamic GnRH release, activating
pituitary–gonadal axis in the late juvenile stage of development [51,52].
The hypothalamus receives afferent inputs from many neuronal
systems for GnRH release [53]. In turn, dopaminergic inputs from
anteroventral periventricular nucleus (AVPV) neurons were recently
described as oneof themost potent inhibitors of GnRHneuron excitabil-
ity [54]. Despite the potential interference on reproductive system, the
repeated treatment with MPH did not affect the onset of puberty,
observed by the day of preputial separation, in this study. There are
few data in literature about the effects of MPH on the pubertal develop-
ment. In juvenile rhesus monkey, delayed occurrence of the testicular
descent (in crescent doses from 3 mg/kg to 25 mg/kg/day) [55],
which is a reliable marker of the initiation of puberty in these animals
[56] was shown. Although the divergence among the results may
be explained by inter-species differences, the absence of studies inpithelium of male rats at PND 100.
MPH 2.5 [14] MPH 5.0 [11]
0.543 ± 0.040 0.591 ± 0.029⁎
23.449 ± 1.193* 26.671 ± 1.097
33.095 ± 1.312 33.092 ± 0.910
93.534 ± 2.982 89.298 ± 1.651
13.569 ± 0.999 13.796 ± 0.575
illed water; MPH 2.5: Methylphenidate 2.5 mg/kg; MPH 5.0: Methylphenidate 5.0 mg/kg.
Table 6
Sexual behavior of adult male rats at PND 100.
Copulatory behavior CTR MPH 2.5 MPH 5.0
Latency to the ﬁrst intromission (s) 161.500 ± 32.947 {8/11} 132.140 ± 46.545 {7/11} 145.560 ± 29.552 {9/12}
No. of intromissions until the ﬁrst ejaculation 20.000 ± 3.290 {8/11} 20.290 ± 4.622 {7/11} 17.890 ± 2.098 {9/12}
Latency to the ﬁrst ejaculation (s) 895.880 ± 94.801 {8/11} 807.570 ± 112.780 {7/11} 789.780 ± 88.675 {9/12}
Latency of the ﬁrst post-ejaculatory intromission (s) 356.880 ± 19.912 {8/11} 290.670 ± 35.460 {6/11} 323.670 ± 21.084 {9/12}
No. of post-ejaculatory intromissions 15.250 ± 0.559 {8/11} 17.670 ± 2.917 {6/11} 15.440 ± 3.727 {9/12}
No. of ejaculations 2.000 (1.500–2.000) {8/11} 2.000 (1.000–2.000) {7/11} 2.000 (2.000–2.000) {9/12}
SIM CTR [11] MPH 2.5 [11] MPH 5.0 [12]
Time spent in male zone (s) 222.090 ± 24.716 234.640 ± 45.632 257.420 ± 59.886
Time spent in female zone (s) 592.180 ± 69.813 433.910 ± 75.543 443.420 ± 74.360
No. of visits in male zone 15.270 ± 1.395 15.000 ± 1.612 14.670 ± 1.685
No. of visits in female zone 18.270 ± 1.743 15.270 ± 0.982 16.000 ± 2.345
Preference score 70.136 ± 4.713 63.240 ± 5.602 61.741 ± 6.763
Data are means ± SEM with the number of animals that displayed the behavior per total number of animals in the group given in curly bracket. ANOVA, p N 0.05. No. of ejaculations is
presented as median (1° and 3° quartile) and was analyzed by the non-parametric test of Kruskal–Wallis, p N 0.05. CTR: distilled water; MPH 2.5: methylphenidate 2.5 mg/kg; MPH 5.0:
methylphenidate 5.0 mg/kg.
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ﬁrst to investigate the relationship of MPH and pubertal development
in male rats.
Evidences reinforce the concept that MPH might promote changes
in sexual hormone proﬁle due to interference on pulsatile release of
hypothalamic GnRH [57], or a possible direct impairment of the Leydig
cell function [19], which may affect the weight of hormone-dependent
organs and hormonal proﬁle. Since MPH is commonly prescribed for
children and adolescents with ADHD and the treatment can be extend-
ed until early adulthood, the present study aimed to evaluate the MPH
effects near 40 days after the end of treatment. In this study, the MPH
treatment did not alter the reproductive organweight as well as testos-
terone levels in adulthood. Organ weight changes are often associated
with treatment-related toxic effects of a drug [58]. It has been demon-
strated that 90 days of treatment at the oral doses of 10 mg/kg but not
5 mg/kg decreased testicular weight in rats [20], corroborating with
our results. In addition, MPH treatment with a substantially higher
dose (100 mg/kg) also led to a reduction in weight of the prostate
being no longer observed after 30 days of the end of treatment [47]. In
this sense, it is suggested that, probably, the doses used in this study,
did not cause changes in hormone-dependent organ weights and if
changes occurred, they were not persistent. In regard to testosterone
level, a decrease in plasma concentration of this hormonewas observed
shortly after 11 week of treatment with MPH (10 mg/kg, gavage) in
adult rats [21]. However, as seen in Adriani et al. [19], this reduction
also appeared to be transient, since there was normalization of the
testicular testosterone concentration two months after treatment
discontinuation (2 mg/kg, i.p.).
Our ﬁndings showed that repeated treatment with MPH altered
sperm morphology observed by an increase in tail abnormality in
MPH 2.5 group in relation to control group but not in MPH 5.0 group.
Nonmonotonic (biphasic) dose–response curve is linked to numerous
chemicals where an increase in the response is observed at the lowest
dose followed by a decrease at the highest dose, or vice versa [59].
Biphasic dose–response relationships of DA and/or its agonists
are reviewed by Calabrese [60] in a wide range of endpoints in rats
(i.e., locomotion, pain sensitivity, diastolic blood pressure, artery
tension, prolactin secretion, oxytocin release, heart rate, memory, and
neuronal adenylate cyclase activity). However, no evidence for this
same pattern to MPH has been described until now. Although the
exact mechanism of DA and NA signaling is not yet identiﬁed, the
relevant presence of DA and NA receptors in testicular tissue and in all
germ cells (pre-and post-meiotic phase) [61,62] suggests that MPH
treatment could have a direct action in these locals.
In the testes, there was an increase in interstitial tissue volume in
both MPH treated groups. Testis consists mainly of the seminiferous
tubules, where the spermatogenesis process occurs [63], and of theinterstitial space between the tubules, which has an endocrine function
[64]. The interstitial compartment consists of Leydig cells, mesenchymal
cells, myoid cells, endothelial cells, pericytes, and macrophages [65].
With the exception of the Leydig cells, the differential count of all inter-
stitial cells was not performed in our study, thereby, it was not possible
to identify whether quantitative changes in other cell types would be
present here. However, the MPH treatment resulted in different chang-
es in cell population of the germinal epithelium observed by the
increase in the number of type A spermatogonia in MPH 5.0 group
while in MPH 2.5 group there was a reduction in the number of
spermatocyte I in the preleptotene/leptotene phase. Spermatogenesis
comprises a highly organized process that produces male haploid
germ cells originated from diploid spermatogonial stem cells [66] and
takes around 48–53 days in rats [67]. It is possible that MPH treatment
has impaired gametogenesis and changes were still present even after
40 days recovery period, probably by affecting germ cells [68]. Also, it
is known that the progression of type A spermatogonia until the stage
of pachytene spermatocyte phase is a FSH dependent process [69]
playing an important regulatory role on the proliferation and renewal
of spermatogonia type A at the initial stages of spermatogenesis
[70,71]. Although in the present study the FSH was not measured, the
results could also suggest an action of MPH on the release of GnRH,
and consequently, altering FSH, since dopaminergic pathways work in
the modulation of GnRH release [53]. Despite changes in spermatogen-
esis which has been demonstrated in several studies [19–21], to date,
there is no basis in the literature that reinforces this hypothesis,
correlating MPH on the release of gonadotropins in male rats.
Regarding sexual behavior, there is evidence supporting the role of
medial preoptic area projections interacting with the mesolimbic DA
system to promote the appetitive and consummatory aspects of sexual
behavior [72]. Indeed, the neurobehavioral functioning in adult life
could be inﬂuenced by environmental, emotional and drug experiences
during development [73–76]. Despite the MPH capacity to change DA
levels during development of the organism and that this neurotransmit-
ter is involved in the establishment of reproductive behavior, no inﬂu-
ences in sexual behavior were observed in this study. Impairment in
sexual behavior was seen in rats after treatment with 4 mg/kg/day
(i.p.) [17], even six weeks after the last MPH injection. It is known that
intraperitoneal administration of MPH, when compared to the same
oral dose has greater central bioavailability to induce locomotor re-
sponse [77]. It is suggested that the divergent results found between
our study and fromBolaños' group [17]might be related to the bioavail-
ability inherent to the administration route used.
The present study shows that repeated treatment with MPH during
late infancy until early adulthoodmay impact the reproductive function
of adult male rats. Data from the literature reinforce the possibility of a
direct action of MPH on spermatogenesis. These results underscore the
128 B.G. Montagnini et al. / Physiology & Behavior 133 (2014) 122–129need for further research aimed at understanding the mechanisms
involved.
5. Conclusions
To summarize, the present study revealed that repeated MPH
administration during periods corresponding childhood to early adult-
hood may have an impact in the testis. This was observed by changes
in the volume of the interstitial tissue of the testicular parenchyma,
and in morphometric parameters, such testicle volumetric composition
and the cell population of germ cells of adult animals. The results could
be attributed to changes in the hypothalamic–pituitary–gonadal axis or
by direct action of MPH in male gonad.
These results reinforce the relevance of further investigation into the
mechanisms by which MPH may act on male germ cells.
Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Acknowledgments
This work was supported by CAPES (Master fellowship to BGM).
References
[1] Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide preva-
lence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry
2007;164:942–8.
[2] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-IV-TR). 4th ed. text revision. Washington, DC: American Psychiatric As-
sociation; 2000.
[3] Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult
attention-deﬁcit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194:
204–11.
[4] Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deﬁcit/
hyperactivity disorder into young adulthood as a function of reporting source and
deﬁnition of disorder. J Abnorm Psychol 2002;111:279–89.
[5] Mannuzza S, Klein R, Bessler A, Malloy P, Lapadula M. Adult psychiatric status of
hyperactive boys grown up. Am J Psychiatry 1998;155:493–8.
[6] Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordina-
tion disorder at age 22 years: a controlled, longitudinal, community-based study. J
Am Acad Child Adolesc Psychiatry 2000;39:1424–31.
[7] Beckman DA, Schneider M, Youreneff M, Tse FL. Juvenile toxicity assessment of d, l-
methylphenidate in rats. Birth Defects Res B 2008;83:48–67.
[8] Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treat-
ment for ADHD. J Atten Disord 2007;10:335–42.
[9] Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription
among school-aged children in a Swiss population: increase in the number of
prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in
patient demographics. J Atten Disord 2010;14:267–72.
[10] Kuczenski R, Segal DS. Effects ofmethylphenidate on extracellular dopamine, seroto-
nin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:
2032–7.
[11] Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, et al. Methyl-
phenidate and cocaine have a similar in vivo potency to block dopamine
transporters in the human brain. Life Sci 1999;65:7–12.
[12] Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Role of dopamine in the thera-
peutic and reinforcing effects of methylphenidate in humans: results from imaging
studies. Eur Neuropsychopharmacol 2002;12:557–66.
[13] Brango CW, Whisnant CS, Goodman RL. A role for catecholaminergic neurons in the
suppression of pulsatile luteinizing hormone secretion in the prepubertal ewe lamb.
Neuroendocrinology 1990;52:448–54.
[14] Ryan KD, Robinson SL. Prolactin or dopamine mediates the induction of puberty by
long days in female ferrets. Endocrinology 1989;125:2605–11.
[15] Vidal B, Pasqualini C, Le Belle N, Holland MC, Sbaihi M, Vernier P, et al. Dopamine
inhibits luteinizing hormone synthesis and release in the juvenile European eel: a
neuroendocrine lock for the onset of puberty. Biol Reprod 2004;71:1491–500.
[16] Andersen SL, Arvanitogiannis A, Pliakas AM, Leblanc C, Carlezon Jr WA. Altered
responsiveness to cocaine in rats exposed to methylphenidate during development.
Nat Neurosci 2002;5:13–4.
[17] Bolaños CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ. Methylphenidate treat-
ment during pre- and periadolescence alters behavioral responses to emotional
stimuli at adulthood. Biol Psychiatry 2003;54:1317–29.
[18] Matsumoto J, Urakawa S, Hori E, de Araujo MFP, Sakuma Y, Ono T, et al. Neuronal
responses in the nucleus accumbens shell during sexual behavior in male rats. J
Neurosci 2012;32:1672–86.[19] Adriani W, Leo D, Guarino M, Natoli A, Di Consiglio E, De Angelis G, et al. Short-term
effects of adolescent methylphenidate exposure on brain striatal gene expression
and sexual/endocrine parameters in male rats. Ann N Y Acad Sci 2006;1074:52–73.
[20] Cansu A, Ekinci O, Ekinci O, Serdaroglu A, Erdogan D, Coskun ZK, et al. Methylpheni-
date has dose-dependent negative effects on rat spermatogenesis: decreased round
spermatids and testicular weight and increased p53 expression and apoptosis. Hum
Exp Toxicol 2011;30:1592–600.
[21] Kianifard D, Hasanzadeh S, Kianifard L. The study of time dependent administration
of methylphenidate on the microscopic indices of spermatogenesis and sperm
analysis in adult rats. J Exp Integr Med 2013;3:121–5.
[22] Marco EV, Adriani W, Ruocco L, Canese R, Sadile AG, Laviola G. Neurobehavioral
adaptations to methylphenidate: the issue of early adolescent. Neurosci Biobehav
Rev 2011;35:1722–39.
[23] Solanto MV. Clinical psychopharmacology of AD/HD: implications for animal
models. Neurosci Biobehav Rev 2000;24:27–30.
[24] U.S. EPA. Harmonization in interspecies extrapolation: use of BW 3/4 as default
method in derivation of the oral RfD (external review draft). Washington, D.C.:
U.S. Environmental Protection Agency; 2006 [EPA/630/R-06/001].
[25] Vieira ML, Dos Santos AH, Silva LS, Fernandes GS, Kiss AC, Moreira EG, et al. Lacta-
tional exposure to sulpiride: assessment of maternal care and reproductive and
behavioral parameters of male rat pups. Physiol Behav 2013;2:76–83.
[26] Robb GW, Amann RP, Killian GJ. Daily sperm production and epididymal sperm
reserves of pubertal and adult rats. J Reprod Fertil 1978;54:103–7.
[27] Fernandes GSA, Arena AC, Fernandez CD, Mercadante A, Barbisan LF, Kempinas WG.
Reproductive effects in male rats exposed to diuron. Reprod Toxicol 2007;23:
106–12.
[28] Perobelli JE, Martinez MF, Franchi CAS, Fernandez CD, Camargo JL, Kempinas WG.
Decreased sperm motility in rats orally exposed to single or mixed pesticides. J
Toxicol Environ Health A 2010;73:991–1002.
[29] Favareto AP, Fernandez CD, da Silva DA, Anselmo-Franci JA, Kempinas WG. Persis-
tent impairment of testicular histology and sperm motility in adult rats treated
with cisplatin at peri-puberty. Basic Clin Pharmacol Toxicol 2011;109:85–96.
[30] Bjorndahl L, Soderlund L, Kvist U. Evaluation of the one-step eosin–nigrosin staining
technique for human sperm vitality assessment. Hum Reprod 2003;18:813–6.
[31] Seed J, Chapin RE, Clegg ED, Dostal LA, Foote RH, Hurtt ME, et al. Methods for
assessing sperm motility, morphology, and counts in the rat, rabbit, and dog: a con-
sensus report. ILSI Risk Science Institute Expert Working Group on Sperm Evalua-
tion. Reprod Toxicol 1996;10:237–44.
[32] Filler R. Methods for evaluation of rats epididymal sperm morphology. In: Chapin
RE, Heindel JH, editors. Male reproductive toxicology. San Diego, California:
Academic Press; 1993. p. 334–43.
[33] Cerri PS, Sasso-Cerri E. Staining methods applied to glycol methacrylate embedded
tissue sections. Micron 2003;34:365–72.
[34] França LR, Godinho CL. Testismorphometry, seminiferous epithelium, cycle length, and
daily sperm production in domestic cats (Felis catus). Biol Reprod 2003;68:1554–61.
[35] Attal J, Courot M. Development testiculaire et etablissement de la spermatogenese
chez le taureau. Ann Biol Anim Biochim Biophys 1963;3:219–41.
[36] Dorst VJ, Sajonski H. Morphometrische untersuchunhen am tubulussystem des
schweinehodens während der postnatalen entwicklug. Monaths Vet Med
1974;29:650–2.
[37] Abercrombie M. Estimation of nuclear population from microtome sections. Anat
Rec 1946;94:239–47.
[38] Amann RP, Almquist JO. Reproductive capacity of dairy bulls. VIII. Direct and indirect
measurement of testicular sperm production. J Dairy Sci 1962;45:774–81.
[39] Hochereau-de Reviers MT, Lincoln GA. Seasonal variation in the histology of the
testis of the red deer, Cervus elaphus. J Reprod Fertil 1978;54:209–13.
[40] França LR, Silva Jr VA, Chiarini-Garcia H, Garcia SK, Debeljuk L. Cell proliferation and
hormonal changes during postnatal development of the testis in the pig. Biol Reprod
2000;63:1629–36.
[41] Gerardin DCC, Bernardi MM, Moreira EG, Pereira OCM. Neuroendocrine and repro-
ductive aspects of adult male rats exposed neonatally to an antiestrogen. Pharmacol
Biochem Behav 2006;83:618–23.
[42] Agmo A. Male rat sexual behavior. Brain Res Protoc 1997;1:203–9.
[43] Agmo A. Lack of opioid or dopaminergic effects on unconditioned sexual incentive
motivation in male rats. Behav Neurosci 2003;117:55–68.
[44] Johnson AM. Analysis of animal weight gains in chronic toxicity studies. J Toxicol
Environ Health 1981;7:307–16.
[45] Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a
characteristic pattern. J Paediatr Child Health 2003;39:180–5.
[46] Ptacek R, Kuzelova H, Paclt I. Effect of stimulants on growth of ADHD children: a
critical review. Act Nerv Super 2009;51:140–6.
[47] Teo S, Stirling D, Thomas S, Hoberman A, Kiorpes A, Khetani V. A 90-day oral gavage
toxicity study of D-methylphenidate and D, L-methylphenidate in Sprague–Dawley
rats. Toxicology 2002;179:183–96.
[48] Glass AR, Swerdloff RS. Nutritional inﬂuences on sexual maturation in the rat. Fed
Proc 1980;39:2360–4.
[49] Holehan AM, Merry BJ. The control of puberty in the dietary restricted female rat.
Mech Ageing Dev 1985;32:179–91.
[50] Sisk CL, Zehr JL. Pubertal hormones organize the adolescent brain and behavior.
Front Neuroendocrinol 2005;26:163–74.
[51] Ebling FJ. The neuroendocrine timing of puberty. Reproduction 2005;129:675–83.
[52] Tsutsumi R, Webster NJ. GnRH pulsatility, the pituitary response and reproductive
dysfunction. Endocr J 2009;56:729–37.
[53] Ciechanowska M, Lapot M, Mateusiak K, Przekop F. Neuroendocrine regulation of
GnRH release and expression of GnRH and GnRH receptor genes in the hypothala-
mus–pituitary unit in different physiological states. Reprod Biol 2010;10:85–124.
129B.G. Montagnini et al. / Physiology & Behavior 133 (2014) 122–129[54] Liu X, Herbison AE. Dopamine regulation of gonadotropin-releasing hormone
neuron excitability in male and female mice. Endocrinology 2013;154:340–50.
[55] Mattison DR, Plant TM, Lin HM, ChenHC, Chen JJ, Twaddle NC, et al. Pubertal delay in
male nonhuman primates (Macaca mulatta) treated with methylphenidate. Proc
Natl Acad Sci 2011;108:16301–6.
[56] Terasawa EI, Fernandez DL. Neurobiological mechanisms of the onset of puberty in
primates. Endocr Rev 2001;22:111–51.
[57] Chatterjee-Chakrabarty S, Miller BT, Collins TJ, Nagamani M. Adverse effects of
methylphenidate on the reproductive axis of adolescent female rats. Fertil Steril
2005;84:1131–8.
[58] Sellers RS, Morton D, Michael B, Roome N, Johnson JK, Yano BL, et al. Society of
Toxicologic Pathology position paper: organ weight recommendations for toxicology
studies. Toxicol Pathol 2007;35:751–5.
[59] Conolly RB, Lutz WK. Nonmonotonic dose–response relationships: mechanistic
basis, kinetic modeling, and implications for risk assessment. Toxicol Sci 2004;
77:151–7.
[60] Calabrese EJ. Dopamine: biphasic dose responses. Crit Rev Toxicol 2001;31:563–83.
[61] Otth C, Torres M, Ramírez A, Fernandez JC, Castro M, Rauch MC, et al. Novel identi-
ﬁcation of peripheral dopaminergic D2 receptor in male germ cells. J Cell Biochem
2007;100:141–50.
[62] Adeoya-Osiguwa SA, Gibbons R, Fraser LR. Identiﬁcation of functional α2- and β-
adrenergic receptors in mammalian spermatozoa. Hum Reprod 2006;21:1555–63.
[63] Griswold MD. The central role of Sertoli cells in spermatogenesis. Semin Cell Dev
Biol 1998;9:411–6.
[64] Dufau ML. Endocrine regulation and communicating functions of the Leydig cell.
Annu Rev Physiol 1988;50:483–508.
[65] Ariyaratne HB, Chamindrani Mendis-Handagama S. Changes in the testis intersti-
tium of Sprague Dawley rats from birth to sexual maturity. Biol Reprod 2000;
62:680–90.
[66] Hess RA, Franca LR. Spermatogenesis and cycle of the seminiferous epithelium. Adv
Exp Med Biol 2008;636:1–15.[67] Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous epithelium
cycle and spermatogonial renewal. Physiol Rev 1972;52:198–236.
[68] U.S. EPA. Guideline for mutagenicity assessment. Washington, D.C.: U.S. Environ-
mental Protection Agency; 1986 [EPA/630/R-98/003].
[69] Boitani C, Politi MG, Menna T. Spermatogonial cell proliferation in organ culture of
immature rat testis. Biol Reprod 1993;48:761–7.
[70] Ding LJ, Yan GJ, Ge QY, Yu F, Zhao X, Diao ZY, et al. FSH acts on the proliferation of
type A spermatogonia via Nur77 that increases GDNF expression in the Sertoli
cells. FEBS Lett 2011;585:2437–44.
[71] Meachem SJ, Wreford NG, Stanton PG, Robertson DM, Mclachlan RI. Follicle-
stimulating hormone is required for the initial phase of spermatogenic restoration
in adult rats following gonadotropin suppression. J Androl 1998;19:725–35.
[72] Stolzenberg DS, Numan M. Hypothalamic interaction with the mesolimbic DA
system in the control of the maternal and sexual behaviors in rats. Neurosci
Biobehav Rev 2011;35:826–47.
[73] Hyman SE. Mood disorders in children and adolescents: an NIMH perspective. Biol
Psychiatry 2001;49:962–9.
[74] Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, Plotsky PM. Long-
term behavioral and neuroendocrine adaptations to adverse early experience. Prog
Brain Res 2000;122:81–103.
[75] Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci
Biobehav Rev 2000;24:417–63.
[76] Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP. Developmental
neurobiology of childhood stress and trauma. Psychiatr Clin North Am 2002;25:
397–426.
[77] Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al.
Comparison between intraperitoneal and oral methylphenidate administration: a
microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000;295:51–7.
